Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
What could be the four HengRui assets picked up by Bristol?
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
GDC-1261 and INR731 enter phase 1, but how do they act?
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
